CoChat

Breast cancer

Open access
Harbeck, Nadia, Penault-Llorca, Frédérique, Cortes, Javier, Gnant, Michael, Houssami, Nehmat, Poortmans, Philip, Ruddy, Kathryn, Tsang, Janice, Cardoso, Fatima · 2019 · Nature Reviews Disease Primers

The DOI matches its Crossref record; 324 of the 324 references it cites were found in a registry or an index.

Abstract

Breast cancer is the most frequent malignancy in women worldwide and is curable in ~70–80% of patients with early-stage, non-metastatic disease. Advanced breast cancer with distant organ metastases is considered incurable with currently available therapies. On the molecular level, breast cancer is a heterogeneous disease; molecular features include activation of human epidermal growth factor receptor 2 (HER2, encoded by ERBB2), activation of hormone receptors (oestrogen receptor and progesterone receptor) and/or BRCA mutations. Treatment strategies differ according to molecular subtype. Management of breast cancer is multidisciplinary; it includes locoregional (surgery and radiation therapy) and systemic therapy approaches. Systemic therapies include endocrine therapy for hormone receptor-positive disease, chemotherapy, anti-HER2 therapy for HER2-positive disease, bone stabilizing agents, poly(ADP-ribose) polymerase inhibitors for BRCA mutation carriers and, quite recently, immunotherapy. Future therapeutic concepts in breast cancer aim at individualization of therapy as well as at treatment de-escalation and escalation based on tumour biology and early therapy response. Next to further treatment innovations, equal worldwide access to therapeutic advances remains the global challenge in breast cancer care for the future.Breast cancer is the most frequent malignancy in women worldwide. Patients are managed on the basis of the key molecular and histological features underpinnin…

Overview

Integrity signals

Registry

Crossref · 10.1038/s41572-019-0111-2

Cites

324 of 324 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 324 references

Research works printed but not linked: 11

  1. Hossain, M. S., Ferdous, S. & Karim-Kos, H. E. Breast cancer in South. Asia: a Bangladeshi perspective. Cancer Epidemiol. 38, 465–470 (2014).
  2. Li, C. I., Malone, K. E. & Daling, J. R. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol. Biomark. Prev. 11, 601–607 (2002).
  3. World Heath Organisation. WHO Classification of Tumours of the Breast, Fourth Edition. (World Health Organization, 2012).
  4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771–784 (2011). · DOI · Paper page
  5. Dare, A. J. et al. Surgical Services for Cancer Care. in Cancer: Disease Control Priorities, Third Edition (Volume 3) (eds. Gelband, H., Jha, P., Sankaranarayanan, R. & Horton, S.) (The International Bank for Reconstruction and Development/The World Bank, 2015).
  6. Sologuren, I., Rodríguez-Gallego, C. & Lara, P. C. Immune effects of high dose radiation treatment: implications of ionizing radiation on the development of bystander and abscopal effects. Transl Cancer Res. 3, 18-31–31 (2014).
  7. Morgan, S., Caudrelier, J.-M. & Clemons, M. Radiotherapy to the primary tumor is associated with improved survival in stage IV breast cancer [abstract]. SABCS P4, 16–06 (2012).
  8. Hou, S., Huh, B., Kim, H. K., Kim, K.-H. & Abdi, S. Treatment of chemotherapy-induced peripheral neuropathy: systematic review and recommendations. Pain Physician 21, 571–592 (2018).
  9. Desmedt, C. et al. Unraveling lobular breast cancer progression and endocrine resistance mechanisms through genomic and immune characterization of matched primary and metastatic samples [abstract]. SABCS GS1–06 (2018).
  10. Cortes, J., Crown, J. & Awada, A. Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC) [abstract]. Eur. Cancer Congr. 51 (Suppl. 3), 1802 (2015).
  11. Hoadley, K. A., Andre, F., Ellis, M. J. & Perou, C. M. Breast cancer intrinsic subtypes (Poster). Nat. Rev. Clin. Oncol. https://www.nature.com/documents/nrclinonc_posters_breastcancer.pdf (2014).

Cited by

See all 3,024

Metadata

Authors
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F.
Affiliations
  • LMU Klinikum (DE)
  • Medical University of Vienna (AT)
  • The University of Sydney (AU)
  • Université Paris Sciences et Lettres (FR)
  • Mayo Clinic (US)
  • University of Hong Kong (HK)
Corresponding author
Harbeck, Nadia
Venue
Nature Reviews Disease Primers
Published
2019-09-23
Volume
5
Issue
1
Pages
66-66
ISSN
2056-676X (ISSN-L)
OpenAlex
W4211005384
Cited by
3,024
References
324
Citations by year
2026: 344 · 2025: 500 · 2024: 536 · 2023: 510 · 2022: 503 · 2021: 425 · 2020: 195 · 2019: 8
FWCI
27.21
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Disease Primers (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • The Sydney eScholarship Repository (The University of Sydney) (submittedVersion)
  • The Sydney eScholarship Repository (The University of Sydney) (submittedVersion, cc-by)
Funders
  • National Institutes of Health (KL2TR002379)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
breast cancer, HER2, oestrogen receptor, progesterone receptor, BRCA mutations, molecular subtypes, endocrine therapy, chemotherapy, HER2-targeted therapy, PARP inhibitors, immunotherapy, locoregional therapy, systemic therapy, treatment de-escalation, treatment escalation, personalized treatment, access to cancer care
MeSH terms
Adult, Breast Neoplasms, Female, Humans, Biomarkers, Tumor, Survivors, Erb-b2 Receptor Tyrosine Kinases, BRCA2 Protein, Ubiquitin-Protein Ligases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Breast cancer. https://app.cochat.ai/papers/10.1038/s41572-019-0111-2
The paper
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019). Breast cancer. Nature Reviews Disease Primers. https://doi.org/10.1038/s41572-019-0111-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.